IL 10?–?Doxorubicin: The dogma and the bone

摘要

Doxorubicin is an anthracycline drug used as frontline chemotherapyof osteosarcoma among other types of cancers.While quite effective in providing a good control over thetumours in some patients, it can cause significant toxicity toorgans such as the heart [1]. Attempts to ameliorate this toxicitywith agents such as dexrazoxane have been successful,but not without complications [2] as will be discussed in thistalk. Pigment epithelium-derived factor (PEDF), a potent antiangiogenicand osteogenetic protein [3], was used to reducethis side-effect, together with an analysis of levels of adenosinetriphosphate (ATP) and reactive oxygen species (ROS). Theeffects of low dose doxorubicin in a clinically relevant dosingmodel will be discussed.